Epstein Files Search

that can be leveraged to drive future growth, with interesting pipeline (antineoplastics at Farmabios, UDCA at PharmaZell) With sales of €100 m plus and EBITDA of €20 m plus Farmabios ... rates of 1.5% in Raubling. Growth rates of 6.5% for Chennai and 7.0% for ■ UDCA - Revenues are expected to increase linearly from EUR 0.8 million in Vizag equal ... from 11/12 to 13/14 level for the business plan period at EUR 1.1 million ■ UDCA capex of EUR 3.0 million from 11/12 to 13/14 ■ Cysteine/Aminoacids - Prices are expected to decrease